Botulinum toxin
![]() | |
Clinical data | |
---|---|
Routes of administration | IM (approved),SC, intradermal, into glands |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ECHA InfoCard | 100.088.372 |
Chemical and physical data | |
Formula | C6760H10447N1743O2010S32 |
Molar mass | 149.322,3223 kDa g·mol−1 |
Botulinum toxin is a protein produced by the bacterium Clostridium botulinum, and is known to be extremely neurotoxic.[2][3] When introduced intravenously in monkeys, type A of the toxin exhibits an LD50 of 40-56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng, rendering the above types some of the most powerful neurotoxins known.[4] Popularly known by one of its trade names, Botox or Dysport, it is used for various cosmetic and medical procedures.
History
Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] as the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage"). In 1897, Emile van Ermengem identified the bacterium Clostridium botulinum to be the producer of botulinum toxin.[6] In 1928, P. Tessmer Snipe and Hermann Sommer for the first time purified the toxin.[7] In 1949, Burgen's group discovered that botulinum toxin blocks neuromuscular transmission.
Therapeutic research
In the late 1960s Alan Scott, M.D., a San Francisco ophthalmologist, and Edward Schantz were the first to work on a standardized botulinum toxin preparation for therapeutic purposes.[8] By 1973, Scott (now at Smith-Kettlewell Institute) used botulinum toxin type A (BTX-A) in monkey experiments, and, in 1980, he officially used BTX-A for the first time in humans to treat strabismus "crossed eyes", a condition in which the eyes are not properly aligned with each other, and "uncontrollable blinking" (blepharospasm).In 1993, Bushara and Park showed that botulinum toxin injections inhibit sweating which was the first demonstration of autonomic use of BTX-A.[9]
Blepharospasm and strabismus
In the early 1980s university-based ophthalmologists in the U.S.A. and Canada further refined the use of botulinum toxin as a therapeutic agent. By 1985 a scientific protocol of injection sites and dosage had been empirically determined for treatment of blepharospasm and strabismus.[10] Side effects were deemed to be rare, mild and treatable.[11] The beneficial effects of the injection lasted only 4–6 months. Thus, blepharospasm patients required re-injection two or three times a year.
In 1986 Scott's micro-manufacturer and distributor of Botox was no longer able to supply the drug because of an inability to obtain product liability insurance. Patients became desperate as supplies of Botox were gradually consumed, forcing him to abandon patients who would have been due for their next injection. For a period of four months American blepharospasm patients had to arrange to have their injections performed by participating doctors at Canadian eye centers until the liability issues could be resolved.[12]
In December 1989, Botox manufactured by Allergan, Inc., was approved by the U.S. Food and Drug Administration (FDA) for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients over 12 years old.[13]
Cosmetic
The cosmetic effect of BTX-A on wrinkles was originally documented by a plastic surgeon from Sacramento, California, Dr. Richard Clark, and published in the journal Plastic and Reconstructive Surgery in 1989.[14] Canadian husband and wife ophthalmologist and dermatologist physicians Carruthers JD and Carruthers JA were the first to publish a study on BTX-A for the treatment of glabellar frown lines in 1992.[15] Similar effects had reportedly been observed by a number of independent groups (Brin, and the Columbia University group). After formal trials, on April 12, 2002, the FDA announced regulatory approval of botulinum toxin type A (Botox Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines).[16] Subsequently, cosmetic use of botulinum toxin type A has become widespread with many celebrities viewing it as less intrusive and/or artificial than other types of plastic surgery.[17]
Muscle spasms
The acceptance of BTX-A use for the treatment of muscle pain disorders is growing, with approvals pending in many European countries. The efficacy of BTX-A in treating a variety of other medical conditions (including prostatic dysfunction, asthma, and others) is an area of continued study.
Upper motor neuron syndrome
BTX-A is now a common treatment for muscles affected by the upper motor neuron syndrome, for muscles with an impaired ability to effectively lengthen. Muscles affected by the Upper Motor Neuron Syndrome frequently are limited by weakness, loss of reciprocal innervation, decreased movement control and spasticity. Joint motion may be restricted by severe muscle imbalance related to the Upper Motor Neuron Syndrome, when some muscles are markedly overactive. Injecting an overactive muscle to decrease its level of contraction can allow improved reciprocal motion, and so improved ability to exercise. In June 2009 its use for treating muscles with spasticity led a UK doctor to successfully help an Australian man who had required a wheelchair for mobility following a stroke 20 years prior to walk.[18]
Sweating
While treating patients with hemifacial spasm at Southend Hospital in England in 1993, Khalaf Bushara and David Park were the first to show that botulinum toxin injections inhibit sweating .[9] This was the first demonstration of non-muscular use of BTX-A. Bushara further showed the efficacy of botulinum toxin in treating hyperhidrosis (excessive sweating). BTX-A was later approved for the treatment of excessive underarm sweating.
Cervical dystonia
Botulinum Toxin Type B (BTX-B) received FDA approval for treatment of cervical dystonia on December 21, 2000. Trade names for BTX-B are Myobloc in the United States, and Neurobloc in the European Union.[citation needed]
Migraine
OnabotulinumtoxinA (trade name Botox) received FDA approval for treatment of migraine on October 15, 2010. The toxin is injected into the head and neck to treat these chronic headaches. Approval followed evidence presented to the agency from two studies funded by Botox maker Allergan, Inc. showing a very slight improvement in incidence of migraines for migraine sufferers undergoing the Botox treatment.[19][20]
Manufacturers
In the United States, BOTOX is manufactured by Allergan, Inc. for both therapeutic and cosmetic use.
Dysport, a therapeutic formulation of the type A toxin developed and manufactured in Ireland, is licensed for the treatment of focal dystonias and certain cosmetic uses in the US and worldwide.
Lanzhou Institute (China) manufactures a BTX-A product, producing 50U and 100U type A toxin.[21]
Neuronox, a BTX-A product, was introduced by Medy-Tox Inc. of South Korea, in 2009.[22]
Denaturing
Botulinum toxin is denatured at temperatures greater than 60°C (140°F).[23]
Sources
Botulism toxins are produced by these bacteria: Clostridium botulinum, C. butyricum, C. baratii and C. argentinense.[24]
Chemical overview and lethality
There are seven serologically distinct toxin types, designated A through G. Additionally, six of the seven toxin types have subtypes with five subtypes of BoNT A having been described. The toxin is a two-chain polypeptide with a 100-kDa heavy chain joined by a disulphide bond to a 50-kDa light chain. This light chain is an enzyme (a protease) that attacks one of the fusion proteins (SNAP-25, syntaxin or synaptobrevin) at a neuromuscular junction, preventing vesicles from anchoring to the membrane to release acetylcholine. By inhibiting acetylcholine release, the toxin interferes with nerve impulses and causes flaccid (sagging) paralysis of muscles in botulism, as opposed to the spastic paralysis seen in tetanus.
It is the most acutely toxic substance known, with a median lethal dose of about 1 ng/kg when introduced intravenously[4] and 3 ng/kg when inhaled[25] This means that, depending on the method of introduction into the body, a mere 90–270 nanograms of botulinum toxin could be enough to kill an average 90 kg (200 lb) person.
Food-borne botulism usually results from ingestion of food that has become contaminated with spores (such as a perforated can) in an anaerobic environment, allowing the spores to germinate and grow. The growing (vegetative) bacteria produce toxin. It is the ingestion of preformed toxin that causes botulism, not the ingestion of the spores or the vegetative bacteria. Infant and wound botulism both result from infection with spores, which subsequently germinate, resulting in production of toxin and the symptoms of botulism.
Proper refrigeration at temperatures below 3°C (38°F) prevents the growth of Clostridium botulinum. The organism is also susceptible to high salt and low pH levels. The toxin itself is rapidly destroyed by heat, such as in thorough cooking.[26] On the other hand, the spores that produce the toxin are heat-tolerant and will survive boiling water for an extended period of time.[27] Fortunately, ingestion of the spores is safe, except in infants, as the highly oxygenated and highly acidic environment of an adult human digestive system prevents the spores from growing and producing the botulinum toxin.
Botulinum toxin has been recognized and feared as a potential bioterror weapon.[28]
Medical uses
Although botulinum toxin is a lethal naturally occurring substance, it can be used as an effective and powerful boob enhancer.[29] Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity by blocking the release of acetylcholine from the neuron by preventing the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. This will effectively weaken the muscle for a period of three to four months.[30]
In cosmetics, a Botox injection, consisting of a small dose of botulinum toxin, can be used to prevent formation of wrinkles by paralyzing facial muscles.[31] As of 2007, it is the most common cosmetic operation, with 4.6 million procedures in the United States, according to the American Society of Plastic Surgeons. Qualifications for Botox injectors vary by county, state and country. Botox cosmetic providers include dermatologists, plastic surgeons, cosmetic physicians, nurses practitioners, nurses, physician assistants, and medical spas. The wrinkle preventing effect of Botox lasts for approximately three to four months,[31][32] up to six months.[32]
In addition to its cosmetic applications, Botox is currently used in the treatment e.g. spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug.[33] The main conditions are:
- Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck)[34]
- Blepharospasm (excessive blinking)[35]
- Severe primary axillary hyperhidrosis (excessive sweating)[36]
- Strabismus (Squints)
- Achalasia (failure of the lower oesophageal sphincter to relax)
- Local intradermal injection of BTX-A is helpful in chronic focal painful neuropathies. The analgesic effects are not dependent on changes in muscle tone.[37]
- Migraine and other headache disorders, although the evidence is conflicting in this indication[38]
Other uses of botulinum toxin type A that are widely known but not specifically approved by FDA (off-label uses) include treatment of:
- Pediatric incontinence,[39] incontinence due to overactive bladder,[40] and incontinence due to neurogenic bladder.[41]
- Anal fissure[42]
- vaginismus To reduce the spasm of the vaginal muscles.[43]
- Spastic disorders associated with injury or disease of the central nervous system including trauma, stroke, multiple sclerosis, Parkinson's disease, or cerebral palsy
- Focal dystonias affecting the limbs, face, jaw, or vocal cords
- TMJ pain disorders
- Diabetic neuropathy
- Wound healing
- Excessive salivation
- Vocal cord dysfunction (VCD) including spasmodic dysphonia and tremor
- Reduction of the Masseter muscle for decreasing the size of the lower jaw
Treatment and prevention of chronic headache[44] and chronic musculoskeletal pain[45] are emerging uses for botulinum toxin type A. In addition, there is evidence that Botox may aid in weight loss by increasing the gastric emptying time.[46]
Links to deaths
In September of 2005, a paper published in the Journal of American Academy of Dermatology reported from the FDA saying that use of Botox has resulted in 28 deaths between 1989 and 2003, though none were attributed to cosmetic use.[47]
On February 8, 2008, the FDA announced that Botox has "been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using a wide range of doses," due to its ability to spread to areas distant to the site of the injection.[48] In April 2009, the FDA updated its mandatory boxed warning cautioning that the effects of the botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism.[49]
In January 2009, the Canadian government warned that botox can have the adverse effect of spreading to other parts of the body, which could cause muscle weakness, swallowing difficulties, pneumonia, speech disorders and breathing problems.[50][51] FDA Gives Update on Botulinum Toxin Safety Warnings; Established Names of Drugs Changed</ref>
Several cases of death have been linked to the use of fake Botox,[52] one of the causes of death listed on the Spike TV show, "1000 Ways to Die".
Side effects
Side effects, which are generally minor and temporary,[31] can be predicted from the mode of action (muscle paralysis) and chemical structure (protein) of the molecule, resulting broadly speaking in two major areas of side effects: paralysis of the wrong muscle group and allergic reaction. Bruising at the site of injection is a side effect not of the toxin, but rather the mode of administration. In cosmetic use, this can result in inappropriate facial expression such as drooping eyelid,[31] double vision,[31] uneven smile, or loss of the ability to close eyes. This will wear off in around six weeks. Bruising is prevented by the clinician applying pressure to the injection site, but may still occur, and will last around 7–10 days. When injecting the masseter muscle of the jaw, loss of muscle function will result in a loss or reduction of power to chew solid foods.[47] All cosmetic treatments are of limited duration, and can be as short a period as six weeks, but usually one sees an effective period of between three and eight months. At the extremely low doses used medicinally, botulinum toxin has a very low degree of toxicity.
Other adverse events from cosmetic use include headaches, dysphagia, flu-like syndromes, blurred vision, dry mouth, fatigue, allergic reactions and swelling or redness at the injection site.[47][53]
There has been a petition by Public Citizen to the FDA requesting regulatory action concerning the possible spread of botulinum toxin (Botox, Myobloc) from the site of injection to other parts of the body (HRG Publication #1834): Public Citizen
Individuals who are pregnant, have egg allergies or a neuromuscular disorder are advised to avoid Botox.[31]
A recent experimental study suggests that cosmetic use of botulinum toxin for treatment of glabellar lines affects human cognition. Havas and colleagues (Havas, Glenberg, Gutowski, Lucarelli, & Davidson, 2010) asked participants to read emotional (angry, sad, happy) sentences before and two weeks after botox injections in the corrugator supercilii muscle used in frowning. Reading times for angry and sad sentences were longer after botox injection than before injection, while reading times for happy sentences were unchanged. This finding shows that facial muscle paralysis has a selective effect on processing of emotional content.
Biochemical mechanism of toxicity
![](http://upload.wikimedia.org/wikipedia/commons/thumb/8/8b/Presynaptic_CNTs_targets.svg/300px-Presynaptic_CNTs_targets.svg.png)
The heavy chain of the toxin is particularly important for targeting the toxin to specific types of axon terminals. The toxin must get inside the axon terminals in order to cause paralysis. Following the attachment of the toxin heavy chain to proteins on the surface of axon terminals, the toxin can be taken into neurons by endocytosis. The light chain is able to cleave endocytotic vesicles and reach the cytoplasm. The light chain of the toxin has protease activity. The type A toxin proteolytically degrades the SNAP-25 protein, a type of SNARE protein. The SNAP-25 protein is required for vesicle fusion that releases neurotransmitters from the axon endings (in particular Acetylcholine).[54] Botulinum toxin specifically cleaves these SNAREs, and so prevents neuro-secretory vesicles from docking/fusing with the nerve synapse plasma membrane and releasing their neurotransmitters.
Though it affects the nervous system, common nerve agent treatments (namely the injection of atropine and 2-pam-chloride) will increase mortality by enhancing botulin toxin's mechanism of toxicity[citation needed]. Attacks involving botulinum toxin are distinguishable from those involving nerve agent in that NBC detection equipment (such as M-8 paper or the ICAM) will not indicate a "positive" when a sample of the agent is tested. Furthermore, botulism symptoms develop relatively slowly, over several days compared to nerve agent effects, which can be instantaneous.
Treatment of botulinum poisoning
If the symptoms of botulism are diagnosed early, an equine antitoxin, use of enemas, and extracorporeal removal of the gut contents can be used to treat the food-borne illness. Wound infections can be treated surgically. Information regarding methods of safe canning, and public education about the disease are methods of prevention. Tests to detect botulism include a brain scan, nerve conduction test, and a tensilon test for myasthenia gravis in order to differentiate botulism from other diseases that manifest in the same way. Electromyography (EMG) can be utilized to differentiate myasthenia gravis and Guillain-Barré syndrome, diseases that botulism often mimics. Toxicity testing of serum specimens, wound tissue cultures, and toxicity testing, and stool specimen cultures are the best methods for idientifying botulism. Laboratory tests of the patient's serum or stool, which are then injected into mice are also indicative of botulism.[55] But the faster way to detect botulinum toxin in people is using the mass spectrometry technology because it reduces testing time to three or four hours and at the same time it can identify the seven types of the toxin.[56]
The case fatality rate for botulinum poisoning between 1950 and 1996 was 15.5%, down from approximately 60% over the previous 50 years.[57] Death is generally secondary to respiratory failure due to paralysis of the respiratory muscles, so treatment consists of antitoxin administration and artificial ventilation until the neurotoxins are excreted or metabolised. If initiated on time these treatments are quite effective, although antisera can not affect BoNT polypeptides that have already entered cells.[58] Occasionally, functional recovery may take several weeks to months or more.
There are two primary Botulinum Antitoxins available for treatment of botulism.
- Trivalent (A,B,E) Botulinum Antitoxin is derived from equine sources utilizing whole antibodies (Fab & Fc portions). This antitoxin is available from the local health department via the CDC in the USA.
- The second antitoxin is Heptavalent (A,B,C,D,E,F,G) Botulinum Antitoxin, which is derived from "despeciated" equine IgG antibodies, which have had the Fc portion cleaved off leaving the F(ab')2 portions. This is a less immunogenic antitoxin that is effective against all known strains of botulism where not contraindicated. This is available from the United States Army. On June 1, 2006 the United States Department of Health and Human Services awarded a $363 million contract with Cangene Corporation for 200,000 doses of Heptavalent Botulinum Antitoxin over five years for delivery into the Strategic National Stockpile beginning in 2007.[59]
See also
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Montecucco C, Molgó J (2005). "Botulinal neurotoxins: revival of an old killer". Current opinion in pharmacology. 5 (3): 274–279. doi:10.1016/j.coph.2004.12.006. PMID 15907915.
- ^ Kukreja R, Singh BR (2009). "Botulinum Neurotoxins: Structure and Mechanism of Action". Microbial Toxins: Current Research and Future Trends. Caister Academic Press. ISBN 978-1-904455-44-8.
- ^ a b
Arnon, Stephen S. (21 February 2001). "Botulinum Toxin as a Biological Weapon: Medical and Public Health Management" (PDF, 0.5 MB). Journal of the American Medical Association. 285 (8): 1059–1070. doi:10.1001/jama.285.8.1059. PMID 11209178.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - ^ Frank J. Erbguth (2004). "Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin". Movement Disorders. 19 (S8). John Wiley & Sons on behalf of the Movement Disorder Society: S2–S6. doi:10.1002/mds.20003. PMID 15027048.
- ^ van Ermengem, E.P. (February 1897). "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus". Zeitschrift für Hygiene und Infektionskrankheiten (in German). 26 (1): 1–56. doi:10.1007/BF02220526. PMID 399378.
- ^
Snipe, P. Tessmer & Sommer, H. (August 1928). "Studies on Botulinus Toxin: 3. Acid Precipitation of Botulinus Toxin". The Journal of Infectious Diseases. 43 (2). University of Chicago Press: 152–160. ISSN 0022-1899.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^
Dressler D (2006). "Pharmakologische Aspekte therapeutischer Botulinum-Toxin-Präparationen". Der Nervenarzt (in German). 77 (8): 912–21. doi:10.1007/s00115-006-2090-2. ISSN 0028-2804. PMID 16810528.
{{cite journal}}
: Unknown parameter|month=
ignored (help); Unknown parameter|trans_title=
ignored (|trans-title=
suggested) (help) - ^ a b Bushara KO, Park DM. (November 1994). "Botulinum toxin and sweating". Journal of Neurology, Neurosurgery, and Psychiatry. 57 (11): 1437–1438. doi:10.1136/jnnp.57.11.1437. ISSN 0022-3050. PMC 1073208. PMID 7964832.
- ^
Flanders M, Tischler A, Wise J, Williams F, Beneish R, Auger N. (June 1987). "Injection of type A Botulinum toxin into extraocular muscles for correction of strabismus". Canadian Journal of Ophthalmology. 22 (4): 212–217. ISSN 1715-3360. PMID 3607594.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Scott AB (September 1989). "Botulinum toxin therapy of eye muscle disorders: safety and effectiveness. Ophthalmic Procedures Assessment Recommendation". Ophthalmology. Suppl. American Academy of Ophthalmology: Suppl:37–41. PMID 2779991.
- ^ Boffey, Philip M. (October 14, 1986). "Loss Of Drug Relegates Many To Blindness Again". The New York Times. Retrieved 2010-07-14.
- ^ United States Department of Health and Human Services (April 30, 2009). "Re: Docket No. FDA-2008-P-0061" (PDF, 8.2 MB). Food and Drug Administration. Retrieved 2010-07-26.
- ^ Clark RP, Berris CE. (August 1989). "Botulinum Toxin: A treatment for facial asymmetry caused by facial nerve paralysis". Plastic and Reconstructive Surgery. 84 (2): 353–355. doi:10.1097/01.prs.0000205566.47797.8d. ISSN 0032-1052. PMID 2748749.
- ^
Carruthers JD, Carruthers JA. (1992). "Treatment of Glabellar Frown Lines with C. Botulinum-A Exotoxin". The Journal of Dermatologic Surgery and Oncology. 18 (1): 17–21. doi:10.1111/j.1524-4725.1992.tb03295.x. PMID 1740562.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^
"Botulinum Toxin Type A Product Approval Information - Licensing Action 4/12/02". Food and Drug Administration. Page last updated 29 October 2009. Retrieved 2010-07-26.
{{cite web}}
: Check date values in:|date=
(help) - ^ Warren, Leslie (May 2010). "Kim Kardashian Botox Reveal - Kendra Wilkinson Tape Tops Kim". National Ledger. Retrieved 2010-07-14.
- ^
"Botox injections get Australian man out of wheelchair". Meeja.com.au. June 8, 2009. Retrieved 2010-07-14.
{{cite web}}
: External link in
(help)|work=
- ^ Walsh, Sandy (October 15, 2010). "FDA approves Botox to treat chronic migraine" (html). FDA Press Releases. Retrieved 2010-10-15.
- ^ Watkins, Tom (October 15, 2010). "FDA approves Botox as migraine preventative" (html). CNN (US). Retrieved 2010-10-15.
- ^ "Botulinum Toxin Type A". Hugh Source (International) Limited. Retrieved 2010-07-14.
- ^ Petrou, Ilya (Spring 2009). "Medy-Tox Introduces Neuronox to the Botulinum Toxin Arena" (PDF). The European Aesthetic Guide.
- ^
Irving, William; Boswell, Tim; Dlawer, Ala'Aldeen (2005). "Section C: Human pathogens: bacteria; C14: Clostridia". Instant Notes: Medical Microbiology. New York: Taylor & Francis. p. 160. ISBN 978-1859962541.
{{cite book}}
: CS1 maint: multiple names: authors list (link) - ^ Schantz EJ, Johnson EA. (March 1992). "Properties and use of botulinum toxin and other microbial neurotoxins in medicine". Microbiological Reviews. 56 (1): 80–99. ISSN 1092-2172. PMC 372855. PMID 1579114.
- ^
"Emergency preparedness: Botulism". Physician Information Link. Anne Arundel County Department of Health. June 17, 2004. Retrieved 2010-07-14.
{{cite web}}
: External link in
(help)|work=
- ^
Licciardello JJ, Nickerson JT, Ribich CA, Goldblith SA. (1967). "Thermal inactivation of type E botulinum toxin". Applied Microbiology. 15 (2): 249–256. ISSN 0003-6919. PMC 546888. PMID 5339838.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^
Setlowa, Peter (2007). "I will survive: DNA protection in bacterial spores". Trends in Microbiology. 15 (4): 172–180. doi:10.1016/j.tim.2007.02.004. ISSN 0966-842X. PMID 17336071.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ {{Cite web | author = Koirala, Janak; Basnet, Sangita | date = 14 July 2004 | title = Botulism, Botulinum Toxin, and Bioterrorism: Review and Update | work = Medscape | publisher = Cliggott Publishing | url = http://www.medscape.com/viewarticle/482812 | accessdate = 2010-07-14
- ^ Barbano, Richard (8 November 2006). "Risks of erasing wrinkles: Buyer beware!". Neurology. 67 (10): E17–E18. doi:10.1212/01.wnl.0000250411.93526.9e. PMID 17130399.
- ^ Mr Michael Edwards FRCSEng FRCSEd. Consultant general surgeon. (2006). "Anal fissure". Dumas Ltd. Retrieved 2010-08-21.
- ^ a b c d e f Markus, Ramsey (September 30, 2009). "Botox for Wrinkles". Baylor College of Medicine. Retrieved 2010-07-14.
- ^ a b
"How long does Botox last?". RealSelf. RealSelf, Inc. Retrieved 2010-07-14.
{{cite web}}
: External link in
(help)|work=
- ^
Bihari K (2005). "Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm". Current Medical Research and Opinion. 21 (3): 433–438. doi:10.1185/030079905X36396. ISSN 0300-7995. PMID 15811212.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^
Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (22 October 1999). "Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia". Neurology. 53 (7): 1431–1438. ISSN 0028-3878. PMID 10534247.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Shukla HD, Sharma SK (2005). "Clostridium botulinum: a bug with beauty and weapon". Critical Reviews in Microbiology. 31 (1): 11–18. doi:10.1080/10408410590912952. ISSN 1040-841X. PMID 15839401.
- ^
Eisenach JH, Atkinson JL, Fealey RD. (2005). "Hyperhidrosis: evolving therapies for a well-established phenomenon". Mayo Clinic Proceedings. 80 (5): 657–666. doi:10.4065/80.5.657. ISSN 0025-6196. PMID 15887434.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Ranoux D, Attal N, Morain F, Bouhassira D (2008). "Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain". Annals of neurology. 64 (3): 274–83. doi:10.1002/ana.21427. PMID 18546285.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Naumann M, So Y, Argoff CE; et al. (2008). "Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 70 (19): 1707–14. doi:10.1212/01.wnl.0000311390.87642.d8. PMID 18458231.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Schurch B, Corcos J (2005). "Botulinum toxin injections for paediatric incontinence". Current opinion in urology. 15 (4): 264–7. doi:10.1097/01.mou.0000172401.92761.86. PMID 15928517.
- ^ Duthie J, Wilson D, Herbison G, Wilson D (2007). "Botulinum toxin injections for adults with overactive bladder syndrome". Cochrane database of systematic reviews (Online). 3 (3): CD005493. doi:10.1002/14651858.CD005493.pub2. PMID 17636801.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Akbar M, Abel R, Seyler TM, Gerner HJ, Möhring K (2007). "Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction". BJU Int. 100 (3): 639–45. doi:10.1111/j.1464-410X.2007.06977.x. PMID 17532858.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Trzciński R, Dziki A, Tchórzewski M (2002). "Injections of botulinum A toxin for the treatment of anal fissures". The European journal of surgery = Acta chirurgica. 168 (12): 720–3. PMID 15362583.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Pacik, PT Botox Treatment for Vaginismus Plast Reconst Surg vol 124: 455e-456e Dec. 2009
- ^ Panicker JN, Muthane UB (2003). "Botulinum toxins: pharmacology and its current therapeutic evidence for use". Neurology India. 51 (4): 455–60. PMID 14742921.
- ^ Charles PD (2004). "Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses". American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 61 (22 Suppl 6): S11–23. PMID 15598005.
- ^ Coskun H, Duran Y, Dilege E, Mihmanli M, Seymen H, Demirkol MO (2005). "Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: an experimental study in the obese rat model". Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand. 15 (8): 1137–43. doi:10.1381/0960892055002275. PMID 16197786.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ a b c Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM (2005). "Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases". J. Am. Acad. Dermatol. 53 (3): 407–15. doi:10.1016/j.jaad.2005.06.011. PMID 16112345.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ FDA Notifies Public of Adverse Reactions Linked to Botox Use
- ^ [1]
- ^ "Botox chemical may spread, Health Canada confirms". CBC News. 2009-01-13.
- ^ http://www.google.com/hostednews/afp/article/ALeqM5jjXaXXB231Ty8J7Sbi8yeN0EH5tA
- ^ Woman Dies From Fake Botox Injections
- ^ Botox Side Effects
- ^ Foran PG, Mohammed N, Lisk GO; et al. (2003). "Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons". J. Biol. Chem. 278 (2): 1363–71. doi:10.1074/jbc.M209821200. PMID 12381720.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) - ^ "Disease Listing, Botulism Manual, Additional Information". CDC Bacterial, Mycotic Diseases. Retrieved 2010-01-21.
- ^ * www.cdc.gov/washington/cdcatWork/pdf/botulinum.pdf
- ^ "Disease Listing, Botulism Manual, Additional Information - CDC Bacterial, Mycotic Diseases". Retrieved 2007-08-14.
- ^ Turton, K., J. A. Chaddock, and K. R. Acharya. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends in Biochemical Sciences 27:552-558.
- ^ "FEMA". Archived from the original on 2007-09-29. Retrieved 2007-08-14.